ArticlePaediatric drugs2024
Adverse Drug Reactions in Children with Congenital Heart Disease: A Scoping Review.
Article in Paediatric drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Preferences for Internet Plus Nursing Services Among Nurses and Patients in China: A Systematic Review of Discrete Choice Experiments.Journal of nursing management · 2026Pooled it
- Artificial intelligence in the identification and prediction of adverse transfusion reactions(ATRs) and implications for clinical management: a systematic review of models and applications.BMC medical informatics and decision making · 2025Pooled it
- Demand analysis of knowledge regarding cardiac rehabilitation among parents of children with congenital heart disease after surgery based on the Kano model.BMC pediatrics · 2026Article
- A clinical decision support system for predicting drug-related adverse effects in pediatric patients with congenital heart disease: Development and retrospective evaluation.The Journal of international medical research · 2026Article
- Inter-specialty differences in the management of febrile neonates on prostaglandin E1.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Young patients with congenital heart disease on psychotropic medications have higher recurrence of cardiac events than those without CHD.Frontiers in cardiovascular medicine · 2026Article
- Pharmacogenetics in pediatric cardiology.Frontiers in pediatrics · 2026Article
- Effectiveness and safety of Guipi Mixture for the treatment of premature ventricular contractions (heart-spleen deficiency syndrome): study protocol for a randomized, double-blind, placebo-controlled, multicentre trial.Frontiers in cardiovascular medicine · 2026Article
- Drug-Related Side Effects and Contributing Risk Factors in Children With Congenital Heart Disease: A Cross-Sectional Study.Health science reports · 2025Article
- Characteristics of pediatric interventional drug trials registered between 2015 and 2024 on ClinicalTrials.gov.Frontiers in pediatrics · 2025Article
- Development and validation of a predictive nomogram for severe adverse drug reactions: a dual-center pharmacovigilance study.Frontiers in pharmacology · 2025Article
- Pharmacovigilance signal detection of psychiatric adverse events induced by third-generation antiepileptic drugs in children.Frontiers in pharmacology · 2025Article
- The Utilization of Acetaminophen for Managing PGE1-Induced Fever in Neonates with Critical Congenital Heart Disease.Children (Basel, Switzerland) · 2024Article
- Addressing Drug-Related Side Effects in Children With Congenital Heart Disease: A Policy Brief.Global pediatric health · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCongenital heart disease (CHD) is one of the leading causes of death. Safe and timely medical interventions, especially in children, can prolong their survival. The drugs prescribed for children with CHD are mainly based on the outcomes of drug therapy in adults with cardiovascular diseases, and their adverse drug reactions (ADRs) might be different. Therefore, the aim of this study was to investigate ADRs in children with CHD.
methodsThis was a scoping review conducted in 2023. PubMed, Web of Science, Scopus, the Cochrane Library, Ovid, ProQuest, and Google Scholar databases were searched. All studies that reported ADRs for children with CHD and were published in English by 1 November 2023 were included in this study. Finally, the results were reported using a content analysis method.
resultsA total of 87 articles were included in the study. The results showed that symptoms/signs/clinical findings, and cardiovascular disorders were the most common ADRs reported in children with CHD. The results also showed that most of the ADRs were reported for prostaglandin E1, amiodarone, prostaglandin E2, dexmedetomidine, and captopril, respectively.
conclusionThe review underscores the wide array of ADRs in children with CHD, particularly in antiarrhythmics, diuretics, beta-blockers, anticoagulants, and vasodilators, which affected cardiovascular, respiratory, endocrine, metabolic, genitourinary, gastrointestinal, and musculoskeletal systems. Tailored treatment is imperative, considering individual patient characteristics, especially in the vulnerable groups. Further research is essential for optimizing dosing, pharmacogenetics, and alternative therapies to enhance patient outcomes in CHD management.
Indexed as
Identifiers
39044096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.